

conditions likely to be encountered upon large-scale production, transportation, storage and pre-usage preparation. The ability to control and produce a stable polymorph with a robust manufacturing process can be key for regulatory approval and marketing. Large scale production processes for high purity 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1H-pyrrole-3-carboxamide can be improved by use of particular polymorphic forms. Accordingly, there is a need for various new crystalline forms of 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1H-pyrrole-3-carboxamide with different chemical and physical stabilities, and formulations and uses of the same.

BRIEF SUMMARY

[0008a] In an aspect of the present disclosure, there is provided a polymorph of 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1H-pyrrole-3-carboxamide, wherein the polymorph is polymorphic Form V, wherein the polymorphic Form V is characterized by having an XRPD pattern comprising peaks at angles 2-theta of 17.8 ± 0.2 , 23.6 ± 0.2 , 23.7 ± 0.2 , 24.2 ± 0.2 , and 25.2 ± 0.2 degrees.

[0008b] In another aspect of the present disclosure, there is provided a composition comprising a polymorph disclosed herein and a pharmaceutically acceptable carrier.

.

[0008c] In a further aspect of the present disclosure, there is provided a method of preparing the polymorph disclosed herein, comprising:

- (a) mixing polymorphic Form I of 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1H-pyrrole-3-carboxamide with aqueous 1-propanol, ethanol, denatured ethanol or aqueous denatured ethanol; and
- (b) slurring the mixture of step (a),

wherein polymorphic Form I of 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1H-pyrrole-3-carboxamide is characterized by having an XRPD pattern comprising peaks at angles 2-theta of 13.0 ± 0.2 , 16.3 ± 0.2 , 19.7 ± 0.2 , 19.9 ± 0.2 , and 20.8 ± 0.2 degrees.

[0008d] In another aspect of the present disclosure, there is provided a polymorph disclosed herein, or the composition disclosed herein, for use in therapy.

[0008e] In a further aspect of the present disclosure there is provided a use of a polymorph disclosed herein or the composition disclosed herein, in the manufacture of a medicament for treating a disease selected from the group consisting of Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), mobility limitation, Chronic Obstructive Pulmonary Disease (COPD), and myasthenia gravis.

[0008f] In another aspect of the present disclosure, there is provided a kit comprising a therapeutically effective amount of the polymorph disclosed herein or the composition disclosed herein and appropriate instructions for preparation and administration of the formulation, side effects of the formulation, and any other relevant information.

[0009] In one example, provided herein are polymorphs of 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1H-pyrrole-3-carboxamide.

CLAIMS

1. A polymorph of 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1H-pyrrole-3-carboxamide, wherein the polymorph is polymorphic Form V, wherein the polymorphic Form V is characterized by having an XRPD pattern comprising peaks at angles 2-theta of 17.8 ± 0.2 , 23.6 ± 0.2 , 23.7 ± 0.2 , 24.2 ± 0.2 , and 25.2 ± 0.2 degrees.
2. The polymorph of claim 1, wherein the polymorph is polymorphic Form V, wherein the polymorphic Form V is characterized by having an XRPD pattern comprising peaks at angles 2-theta of 5.9 ± 0.2 , 13.6 ± 0.2 , 16.6 ± 0.2 , 17.8 ± 0.2 , 18.4 ± 0.2 , 23.6 ± 0.2 , 23.7 ± 0.2 , 24.2 ± 0.2 , 25.2 ± 0.2 , and 26.5 ± 0.2 degrees.
3. The polymorph of claim 1 or 2, wherein the polymorph is polymorphic Form V, wherein the polymorphic Form V is characterized by having an XRPD pattern substantially as shown in FIG. 5A.
4. The polymorph of any one of claims 1-3, wherein the polymorph is polymorphic Form V, wherein the polymorphic Form V is characterized by having a DSC graph substantially as shown in FIG. 5B.
5. The polymorph of any one of claims 1-4, wherein the polymorph is polymorphic Form V, wherein the polymorphic Form V is characterized by having a melting endotherm onset at 190 ± 0.2 °C as determined by DSC.
6. The polymorph of any one of claims 1-5, wherein the polymorph is polymorphic Form V, wherein the polymorphic Form V is characterized by having a TGA graph substantially as shown in FIG. 5B.
7. The polymorph of any one of claims 1-6, wherein the polymorph is polymorphic Form V, wherein the polymorphic Form V is characterized by having a GVS graph substantially as shown in FIG. 5C.
8. The polymorph of any one of claims 1-7, wherein the polymorph is polymorphic Form V, wherein the polymorphic Form V has less than 0.05% moisture uptake over 0-90% relative humidity range as determined by GVS.
9. A composition comprising a polymorph of any one of claims 1-8 and a pharmaceutically acceptable carrier.
10. A method of preparing the polymorph of any one of claims 1-8, comprising:

(a) mixing polymorphic Form I of 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1H-pyrrole-3-carboxamide with aqueous 1-propanol, ethanol, denatured ethanol or aqueous denatured ethanol; and

(b) slurring the mixture of step (a),

wherein polymorphic Form I of 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1H-pyrrole-3-carboxamide is characterized by having an XRPD pattern comprising peaks at angles 2-theta of 13.0 ± 0.2 , 16.3 ± 0.2 , 19.7 ± 0.2 , 19.9 ± 0.2 , and 20.8 ± 0.2 degrees.

11. A polymorph of any one of claims 1-8, or the composition of claim 9, for use in therapy.

12. Use of a polymorph of any one of claims 1-8 or the composition of claim 9, in the manufacture of a medicament for treating a disease selected from the group consisting of Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), mobility limitation, Chronic Obstructive Pulmonary Disease (COPD), and myasthenia gravis.

13. The use of claim of claim 12, wherein the disease is Amyotrophic Lateral Sclerosis (ALS).

14. The use of claim of claim 12, wherein the disease is Spinal Muscular Atrophy (SMA).

15. The use of claim of claim 12, wherein the disease is Chronic Obstructive Pulmonary Disease (COPD).

16. A kit comprising a therapeutically effective amount of the polymorph of any one of claims 1-8 or the composition of claim 9 and appropriate instructions for preparation and administration of the formulation, side effects of the formulation, and any other relevant information.